Gyrate Atrophy of the choroid and retina (GACR) is a rare, progressive inherited retinal disease that ultimately leads to severe vision loss. For decades, the primary focus of potential gene therapies has been directly targeting the eye. However, recent advancements in the field are shifting this paradigm, suggesting that treating the liver might be the key to saving vision.
The Systemic Nature of Gyrate Atrophy
Gyrate Atrophy is caused by bi-allelic pathogenic variants in the OAT gene, which encodes the enzyme ornithine aminotransferase. This enzyme is crucial for breaking down the amino acid ornithine. When the enzyme is deficient, ornithine accumulates to toxic levels in the blood—a condition known as hyperornithinemia.
While the most devastating symptoms of GACR are ocular, including night blindness, cataracts, and progressive chorioretinal degeneration, the root cause is a systemic metabolic defect. The retina and choroid are particularly sensitive to high levels of ornithine, leading to the characteristic circular patches of atrophy that give the disease its name.
The Shift to Liver-Directed Therapy
Historically, gene therapy for retinal diseases has involved injecting a functional copy of the defective gene directly into the eye (subretinal or intravitreal injections). While this approach has seen success in other conditions, such as RPE65-mediated inherited retinal disease, it presents unique challenges for Gyrate Atrophy.
Direct ocular gene therapy for GACR only corrects the enzyme deficiency in the specific retinal cells that receive the new gene. It does not address the systemic hyperornithinemia. Because the toxic ornithine continues to circulate in the blood and bathe the eye, the unprotected cells remain vulnerable to damage.
Recent studies have explored a different approach: liver-directed gene therapy. The liver is the primary organ responsible for amino acid metabolism. By introducing a functional OAT gene into liver cells, researchers aim to restore the body's ability to process ornithine systemically.
Broadening the Therapeutic Impact
Preclinical models have shown promising results for this systemic approach. By reducing circulating ornithine levels, liver-directed gene therapy has the potential to halt or significantly slow the progression of retinal degeneration across the entire eye, rather than just in localized areas treated by direct injection.
Furthermore, some researchers are investigating a combined approach—utilizing both intraocular and intravenous gene delivery. This dual strategy aims to provide immediate, localized protection to the retina while simultaneously addressing the underlying systemic metabolic defect through the liver.
Looking Ahead
As research progresses, the focus on liver-directed and combined gene therapies represents a significant step forward in the quest for a cure for Gyrate Atrophy. By addressing the root metabolic cause of the disease, these approaches offer hope for a more comprehensive and lasting treatment for patients.
*
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Genetic testing and clinical management should be performed by qualified healthcare professionals.